Associations of anti-hypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias

Journal of Alzheimer's Disease

Volumn 26, Issue 4, 2011, Pages 699-708

  Davies, Neil M ^a,b   Kehoe, Patrick G ^b   Ben Shlomo, Yoav ^a   Martin, Richard M ^a,b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

All cognitive disorders dementia; Alzheimer's disease; case control studies; risk factors in epidemiology; vascular dementia

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THIAZIDE DIURETIC AGENT;

AGED; ALZHEIMER DISEASE; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CASE CONTROL STUDY; COMORBIDITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMENTIA; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTIINFARCT DEMENTIA; NEUROPROTECTION; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SMOKING; SOCIAL STATUS;

EID: 80054843547     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-110347     Document Type: Article

References (44)

1. Miners J, Baig S, Palmer J, Palmer L, Kehoe P, Love S (2008) Abeta-degrading enzymes in Alzheimers disease. Brain Pathol 18, 240-252.
2. Grinberg LT, Heinsen H (2010) Toward a pathological definition of vascular dementia. J Neurol Sci 299, 136-138.
3. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study(MRC CFAS) (2001) Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet 357, 169-175.
4. Hanon O, Seux M, Lenoir H, Rigaud A, Forette F (2004) Prevention of dementia and cerebroprotection with antihypertensive drugs. Curr Hypertens Rep 6, 201-207. (Pubitemid 39359563)
5. Kehoe P, Miners S, Love S (2009) Angiotensins in Alzheimers disease-friend or foe? Trends Neurosci 32, 619-628.
6. Skoog I, Gustafson D (2006) Update on hypertension and Alzheimers disease. Neurol Res 28, 605-611.
7. Jagust W (2000) Neuroimaging in dementia. Neurol Clin 18, 885-902.
8. Kalaria R (2009) Linking cerebrovascular defense mechanisms in brain ageing and Alzheimers disease. Neurobiol Aging 30, 1512-1514.
9. Shiraishi H, Chang C, Kanno H, Yamamoto I (2004) The relationship between cerebral blood flowand cognitive function in patients with brain insult of various etiology. J Clin Neurosci 11, 138-141. (Pubitemid 38248411)
10. Buée L, Hof P, Bouras C, Delacourte A, Perl D, Morrison J, Fillit H (1994) Pathological alterations of the cerebral microvasculature in Alzheimers disease and related dementing disorders. Acta Neuropathol 87, 469-480. (Pubitemid 24128974)
11. Arendash G, Su G, Crawford F, Bjugstad K, MullanM(1999) Intravascular beta]-amyloid infusion increases blood pressure: implications for a vasoactive role of beta]-amyloid in the pathogenesis of Alzheimers disease. Neurosci Lett 268, 17-20. (Pubitemid 29292534)
12. Palmer J, Baig S, Kehoe P, Love S (2009) Endothelin-Converting enzyme-2 is increased in Alzheimers disease and up-regulated by A beta. Am J Pathol 175, 262-270.
13. Fogari R, Mugellini A, Zoppi A, Derosa G, Pasotti C, Fogari E, Preti P (2003) Influence of losartan and atenolol on memory function in very elderly hypertensive patients. J Hum Hypertens 17, 781-785. (Pubitemid 37441435)
14. Li N, Lee A, Whitmer R, Kivipelto M, Lawler E, Kazis L, Wolozin B (2010) Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 340, b5465.
15. Walker A (1996) Confounding by indication. Epidemiology 7, 335-336.
16. General Practice Research Database (GPRD) (2010) The database. http://www.gprd.com/products/database.asp.
17. Khan N, Harrison S, Rose P (2010) Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pract 60, e128-e136.
18. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA (2000) Statins and the risk of dementia. Lancet 356, 1627-1631.
19. World Health Organization. The anatomical therapeutic chemical classification system with defined daily doses, http://www.who.int/ classifications/atcddd/en/.
20. Salas M, Hotman A, Stricker B (1999) Confounding by indication: an example of variation in the use of epidemiologic terminology. Am J Epidemiol 149, 981-983. (Pubitemid 29246861)
21. McMahon AD (2003) Approaches to combat with confounding by indication in observational studies of intended drug effects. Pharmacoepidemiol Drug Saf 12, 551-558. (Pubitemid 37220641)
22. Altman DG, Bland JM (2003) Statistics Notes: Interaction revisited: the difference between two estimates. BMJ 326, 219. (Pubitemid 36143396)
23. den Heijer T, van der Lijn F, Koudstaal PJ, Hofman A, van der Lugt A, Krestin GP, Niessen WJ, BretelerMMB(2010) A 10-year follow-up of hippocampal volume on magnetic resonance imaging in early dementia and cognitive decline. Brain 133, 1163-1172.
24. Suissa S (2008) Immortal time bias in pharmacoepidemiology. Am J Epidemiol 167, 492-499. (Pubitemid 351264145)
25. Zou K, Yamaguchi H, Akatsu H, Sakamoto T, Ko M, Mizoguchi K, Gong J, YuW, Yamamoto T, Kosaka K (2007) Angiotensin-converting enzyme converts amyloid-protein 1-42 (A 1-42) to A 1-40, and its inhibition enhances brain A deposition. J Neurosci 27, 8628-8635.
26. Rozzini L, Chilovi V (2008) Antihypertensive medications influence the rate of conversion from mild cognitive impairment to Alzheimer disease. Arch Neurol 65, 993-995.
27. Rosenberg P, MielkeM, Tschanz J, Cook L, Stat M, Corcoran C, Hayden K, Norton M, Rabins P, Green R (2008) Effects of cardiovascular medications on rate of functional decline in Alzheimer disease. Am J Geriatr Psychiatry 16, 883-892.
28. Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C, Waldman A, Walton I, Poulter R, Ma S (2008) Incident dementia and blood pressure lowering in the Hypertension in theVery ElderlyTrial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol 7, 683-689.
29. Fogari R, Mugellini A, Zoppi A, Marasi G, Pasotti C, Poletti L, Rinaldi A, Preti P (2004) Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension. Eur J Clin Pharmacol 59, 863-868. (Pubitemid 38333676)
30. Barnes J, Barnes N, Costall B, Horovitz Z, Naylor R (1989) Angiotensin II inhibits the release of 3H acetylcholine from rat entorhinal cortex in vitro. Brain Res 491, 136-143. (Pubitemid 19159084)
31. Barnes J, Barnes N, Costall B, Horovitz Z, Ironside J, Naylor R, Williams T (1990) Angiotensin II inhibits cortical cholinergic function: implications for cognition. J Cardiovasc Pharmacol 16, 234-238. (Pubitemid 20222645)
32. Barnes J, Barnes N, Costall B, Horovitz Z, Ironside J, Naylor R, Williams T (1990) Angiotensin II inhibits acetylcholine release from human temporal cortex: implications for cognition. Brain Res 507, 341-343. (Pubitemid 20054121)
33. Anderson C, Teo K, Gao P, Arima H, Dans A, Unger T, Commerford P, Dyal L, Schumacher H, Pogue J (2011) Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol 10, 43-53.
34. Odili AN, Richart T, Staessen JA (2011) Methodological issues in the assessment of cognitive decline in ONTARGET and TRANSCEND. Lancet Neurol 10, 22-24.
35. Staessen JA, Thijs L, Richart T, Odili AN, Birkenhager WH (2011) Placebo-controlled trials of blood pressure-lowering therapies for primary prevention of Dementia. Hypertension 57, e6-e7.
36. Staessen JA, Richart T, Birkenhager WH (2007) Less atherosclerosis and lower blood pressure for a meaningful life perspective with more brain. Hypertension 49, 389-400.
37. Dunn N, Mullee M, Perry VH, Holmes C (2005) Association between dementia and infectious disease: evidence from a case-control study. Alzheimer Dis Assoc Disord 19, 91-94. (Pubitemid 41073086)
38. Lewis JD, Brensinger C (2004) Agreement between GPRD smoking data: a survey of general practitioners and a population based survey. Pharmacoepidemiol Drug Saf 13, 437-441. (Pubitemid 38996854)
39. Sink K, Leng X, Williamson J, Kritchevsky S, Yaffe K, Kuller L, Yasar S, Atkinson H, Robbins M, Psaty B (2009) Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study. Arch Intern Med 169, 1195-1202.
40. Furberg C, Pitt B (2001) Are all angiotensin-converting enzyme inhibitors interchangeable? J Am Coll Cardiol 37, 1456-1460.
41. Jouquey S, Mathieu MN, Hamon G, Chevillard C (1995) Effect of chronic treatment with trandolapril or enalapril on brain ACE activity in spontaneously hypertensive rats. Neuropharmacology 34, 1689-1692. (Pubitemid 26005616)
42. Sakaguchi K, Chai S, Jackson B, Johnston C, Mendelsohn F (1987) Blockade of angiotensin converting enzyme in circumventricular organs of the brain after oral lisinopril administration demonstrated by quantitative in vitro autoradiography. Clin Exp Pharmacol Physiol 14, 155-158. (Pubitemid 18002631)
43. Duron E, Hanon O (2010) Antihypertensive treatments, cognitive decline, and dementia. J Alzheimers Dis 20, 903-914.
44. Jordan K, Porcheret M, Croft P (2004) Quality of morbidity coding in general practice computerized medical records: a systematic review. Fam Pract 21, 396-412. (Pubitemid 39162008)